Back to Search Start Over

Early Death and Survival of Patients With Acute Promyelocytic Leukemia in ATRA Plus Arsenic Era: A Population-Based Study.

Authors :
Zhu HH
Ma YF
Yu K
Ouyang GF
Luo WD
Pei RZ
Xu WQ
Hu HX
Mo SP
Xu XH
Lan JP
Shen JP
Shou LH
Qian SX
Feng WY
Zhao P
Jiang JH
Hu BL
Zhang J
Qian SY
Wu GQ
Wu WP
Qiu L
Li LJ
Lang XH
Chen S
Chen LL
Guo JB
Cao LH
Jiang HF
Xia YM
Le J
Zhao JZ
Huang J
Zhang YF
Lv YL
Hua JS
Hong YW
Zheng CP
Wang JX
Hu BF
Chen XH
Zhang LM
Tao S
Xie BS
Kuang YM
Luo WJ
Su P
Guo J
Wu X
Jiang W
Zhang HQ
Zhang Y
Chen CM
Xu XF
Guo Y
Tu JM
Hu S
Yan XY
Yao C
Lou YJ
Jin J
Source :
Frontiers in oncology [Front Oncol] 2021 Nov 16; Vol. 11, pp. 762653. Date of Electronic Publication: 2021 Nov 16 (Print Publication: 2021).
Publication Year :
2021

Abstract

Most randomized trials for acute promyelocytic leukemia (APL) have investigated highly selected patients under idealized conditions, and the findings need to be validated in the real world. We conducted a population-based study of all APL patients in Zhejiang Province, China, with a total population of 82 million people, to assess the generalization of all-trans retinoic acid (ATRA) and arsenic as front-line treatment. The outcomes of APL patients were also analyzed. Between January 2015 and December 2019, 1,233 eligible patients were included in the final analysis. The rate of ATRA and arsenic as front-line treatment increased steadily from 66.2% in 2015 to 83.3% in 2019, with no difference among the size of the center (≥5 or <5 patients per year, p = 0.12) or age (≥60 or <60 years, p = 0.35). The early death (ED) rate, defined as death within 30 days after diagnosis, was 8.2%, and the 3-year overall survival (OS) was 87.9% in the whole patient population. Age (≥60 years) and white blood cell count (>10 × 10 <superscript>9</superscript> /L) were independent risk factors for ED and OS in the multivariate analysis. This population-based study showed that ATRA and arsenic as front-line treatment are widely used under real-world conditions and yield a low ED rate and a high survival rate, which mimic the results from clinical trials, thereby supporting the wider application of APL guidelines in the future.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Zhu, Ma, Yu, Ouyang, Luo, Pei, Xu, Hu, Mo, Xu, Lan, Shen, Shou, Qian, Feng, Zhao, Jiang, Hu, Zhang, Qian, Wu, Wu, Qiu, Li, Lang, Chen, Chen, Guo, Cao, Jiang, Xia, Le, Zhao, Huang, Zhang, Lv, Hua, Hong, Zheng, Wang, Hu, Chen, Zhang, Tao, Xie, Kuang, Luo, Su, Guo, Wu, Jiang, Zhang, Zhang, Chen, Xu, Guo, Tu, Hu, Yan, Yao, Lou, Jin and the APL Cooperative Group of Zhejiang Province.)

Details

Language :
English
ISSN :
2234-943X
Volume :
11
Database :
MEDLINE
Journal :
Frontiers in oncology
Publication Type :
Academic Journal
Accession number :
34868978
Full Text :
https://doi.org/10.3389/fonc.2021.762653